Organogenesis Inc. said yesterday that its wound-healing cell therapy Apligraf is the 1st of its kind to significantly change the genomic profile of a treated chronic wound. The claim was supported by new research done at the University of Miami and published in the journal Science Translational Medicine. The team applied Apligraf to a chronic venous leg […]
LimFlow taps ex-Direct Flow GM Rose as CEO LimFlow said this week that it tapped former Direct Flow Medical VP and GM Daniel Rose as its new chief executive, with former co-founder & CEO Timothy Lenihan transitioning to chief technology officer. LimFlow is developing a device to create percutaneous venous arterialization in the foot to treat end-stage critical limb […]
Organogenesis said yesterday that it raised $30 million from existing investors to back its expansion plans. Canton, Mass.-based Organogenesis makes a line of regenerative medicine products designed to heal wounds. The company said it plans to use the proceeds to expand its sales force and commercial operations and to widen the reach of its PuraPly collagen […]
Former Advanced BioHealing executive Todd Clawson last week pleaded guilty to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing. Federal prosecutors accused Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic foot ulcer treatment with a […]
MiMedx (NSDQ:MDXG) CEO Pete Petit last week renewed a beef with regenerative medicine rival Organogenesis, accusing that company of being behind a short-seller’s letter advising investors to bet against MiMedx. Early this year, Marietta, Ga.-based MiMedx bailed out of a lawsuit against Canton, Mass.-based Organogenesis alleging “malicious actions” and interference from Organogenesis in the U.S. Veterans Affairs Dept. decision to stop using its […]
Organogenesis yesterday it is releasing results from a comparative effectiveness analysis of its Apligraf and Dermagraf artificial skin grafts showing superior performance compared to its competitors, and released data from a previous study of its graft being used to treat diabetic foot ulcers. The results will be reported at the Symposium on Advanced Wound Care’s […]
Organogenesis said today that a comparative effectiveness analysis of its Apligraf skin substitute has shown improved outcomes over competitor MiMedx‘s (NSDQ:MDXG) Epifix. The study, published this week in Wound Repair & Regeneration, examined healing rates of patients with diabetic foot ulcers treated either with Apligraf or Epifix. Data from the 218-patient, 99-center retrospective study showed a 97% […]
January 6, 2015 by Mark Hollmer
January 6, 2015 by Brad Perriello
A sales agent for Organogenesis Inc. is accused of stealing some $350,000 worth of skin grafts made by the Massachusetts regenerative medicine company, according to news reports.
Mercy Philadelphia Hospital accused Gary Dudek of the theft after an audit exposed the missing grafts, according to the New York Daily News.